CogState Schizophrenia Battery

Calibration and cross-validation of MCCB and CogState in schizophrenia

Authors: Jane Lees, Eve Applegate, Richard Emsley, Shôn Lewis, Panayiota Michalopoulou, Tracey Collier, Cristina Lopez-Lopez, Shitij Kapur, Gahan J Pandina, Richard J Drake

Journal: Psychopharmacology

Year Published: 2015

Rationale: Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of […]

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

Authors: L Fredrik Jarskog, Martin T Lowy, Richard A Grove, Richard S E Keefe, Joseph P Horrigan, M Patricia Ball, Alan Breier, Robert W Buchanan, Cameron S Carter, John G Csernansky, Donald C Goff, Michael F Green, Joshua T Kantrowitz, Matcheri S Keshavan, Marc Laurelle, Jeffrey A Lieberman, Stephen R Marder, Paul Maruff, Robert P McMahon, Larry J Seidman, Margaret A Peykamian

Journal: Schizophrenia Research

Year Published: 2015

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). […]

Back to Publications